Logo image of DBD

DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis

NYSE:DBD - New York Stock Exchange, Inc. - US2536512021 - Common Stock

45.9  +1.41 (+3.17%)

After market: 45.9 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to DBD. DBD was compared to 32 industry peers in the Technology Hardware, Storage & Peripherals industry. There are concerns on the financial health of DBD while its profitability can be described as average. DBD is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year DBD was profitable.
In the past year DBD had a positive cash flow from operations.
DBD had negative earnings in 4 of the past 5 years.
In multiple years DBD reported negative operating cash flow during the last 5 years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B

1.2 Ratios

Looking at the Return On Assets, with a value of 0.57%, DBD is in line with its industry, outperforming 51.61% of the companies in the same industry.
The Return On Equity of DBD (2.08%) is better than 67.74% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.90%, DBD is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for DBD is significantly below the industry average of 16.39%.
The last Return On Invested Capital (8.90%) for DBD is above the 3 year average (4.34%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.57%
ROE 2.08%
ROIC 8.9%
ROA(3y)3.95%
ROA(5y)-0.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)4.34%
ROIC(5y)4.03%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 200 300

1.3 Margins

With a Profit Margin value of 0.58%, DBD perfoms like the industry average, outperforming 54.84% of the companies in the same industry.
With a decent Operating Margin value of 7.68%, DBD is doing good in the industry, outperforming 67.74% of the companies in the same industry.
DBD's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 24.64%, DBD is not doing good in the industry: 61.29% of the companies in the same industry are doing better.
DBD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.68%
PM (TTM) 0.58%
GM 24.64%
OM growth 3Y7.99%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.9%
GM growth 5Y3.02%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
DBD has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, DBD has less shares outstanding
Compared to 1 year ago, DBD has an improved debt to assets ratio.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B 5B

2.2 Solvency

DBD has an Altman-Z score of 1.75. This is a bad value and indicates that DBD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.75, DBD is in line with its industry, outperforming 41.94% of the companies in the same industry.
DBD has a debt to FCF ratio of 11.33. This is a negative value and a sign of low solvency as DBD would need 11.33 years to pay back of all of its debts.
The Debt to FCF ratio of DBD (11.33) is comparable to the rest of the industry.
DBD has a Debt/Equity ratio of 1.03. This is a high value indicating a heavy dependency on external financing.
DBD has a worse Debt to Equity ratio (1.03) than 61.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF 11.33
Altman-Z 1.75
ROIC/WACC0.86
WACC10.38%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 1.45 indicates that DBD should not have too much problems paying its short term obligations.
DBD's Current ratio of 1.45 is in line compared to the rest of the industry. DBD outperforms 45.16% of its industry peers.
DBD has a Quick Ratio of 1.45. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.96, DBD perfoms like the industry average, outperforming 48.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 0.96
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

DBD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 322.18%, which is quite impressive.
DBD shows a small growth in Revenue. In the last year, the Revenue has grown by 2.88%.
Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.86% on average per year.
EPS 1Y (TTM)322.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.23%
Revenue 1Y (TTM)2.88%
Revenue growth 3Y-1.23%
Revenue growth 5Y-3.86%
Sales Q2Q%-1.73%

3.2 Future

Based on estimates for the next years, DBD will show a very strong growth in Earnings Per Share. The EPS will grow by 148.43% on average per year.
The Revenue is expected to grow by 1.22% on average over the next years.
EPS Next Y974%
EPS Next 2Y268.62%
EPS Next 3Y148.43%
EPS Next 5YN/A
Revenue Next Year0.24%
Revenue Next 2Y0.91%
Revenue Next 3Y1.22%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 7.77, the valuation of DBD can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 96.77% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 28.29. DBD is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 9.21, which indicates a very decent valuation of DBD.
90.32% of the companies in the same industry are more expensive than DBD, based on the Price/Forward Earnings ratio.
DBD is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 7.77
Fwd PE 9.21
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, DBD is valued cheaply inside the industry as 96.77% of the companies are valued more expensively.
77.42% of the companies in the same industry are more expensive than DBD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 17.76
EV/EBITDA 5.9
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as DBD's earnings are expected to grow with 148.43% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y268.62%
EPS Next 3Y148.43%

More info and screens

0

5. Dividend

5.1 Amount

DBD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIEBOLD NIXDORF INC

NYSE:DBD (1/21/2025, 7:00:00 PM)

After market: 45.9 0 (0%)

45.9

+1.41 (+3.17%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-12 2025-02-12/bmo
Inst Owners102.4%
Inst Owner Change-0.01%
Ins Owners1.65%
Ins Owner Change0.62%
Market Cap1.72B
Analysts83.33
Price Target63.75 (38.89%)
Short Float %2.22%
Short Ratio4.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.86%
Min EPS beat(2)-52.17%
Max EPS beat(2)8.44%
EPS beat(4)3
Avg EPS beat(4)118.34%
Min EPS beat(4)-52.17%
Max EPS beat(4)407.85%
EPS beat(8)5
Avg EPS beat(8)-120.62%
EPS beat(12)6
Avg EPS beat(12)-123.01%
EPS beat(16)8
Avg EPS beat(16)-94.49%
Revenue beat(2)1
Avg Revenue beat(2)0.3%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)1.85%
Revenue beat(4)3
Avg Revenue beat(4)0.47%
Min Revenue beat(4)-1.24%
Max Revenue beat(4)1.85%
Revenue beat(8)3
Avg Revenue beat(8)-0.94%
Revenue beat(12)3
Avg Revenue beat(12)-2.49%
Revenue beat(16)4
Avg Revenue beat(16)-2.47%
PT rev (1m)8.7%
PT rev (3m)8.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-35.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-29.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.13%
Valuation
Industry RankSector Rank
PE 7.77
Fwd PE 9.21
P/S 0.45
P/FCF 17.76
P/OCF 14.92
P/B 1.62
P/tB N/A
EV/EBITDA 5.9
EPS(TTM)5.91
EY12.88%
EPS(NY)4.98
Fwd EY10.86%
FCF(TTM)2.58
FCFY5.63%
OCF(TTM)3.08
OCFY6.7%
SpS101.09
BVpS28.37
TBVpS-10.62
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.57%
ROE 2.08%
ROCE 11.26%
ROIC 8.9%
ROICexc 9.9%
ROICexgc 26.74%
OM 7.68%
PM (TTM) 0.58%
GM 24.64%
FCFM 2.56%
ROA(3y)3.95%
ROA(5y)-0.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)4.34%
ROIC(5y)4.03%
ROICexc(3y)5.63%
ROICexc(5y)5.08%
ROICexgc(3y)27.53%
ROICexgc(5y)22.99%
ROCE(3y)5.5%
ROCE(5y)5.1%
ROICexcg growth 3Y-10.37%
ROICexcg growth 5YN/A
ROICexc growth 3Y-2.83%
ROICexc growth 5YN/A
OM growth 3Y7.99%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.9%
GM growth 5Y3.02%
F-Score6
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF 11.33
Debt/EBITDA 2.59
Cap/Depr 14%
Cap/Sales 0.49%
Interest Coverage 250
Cash Conversion 27.28%
Profit Quality 437.39%
Current Ratio 1.45
Quick Ratio 0.96
Altman-Z 1.75
F-Score6
WACC10.38%
ROIC/WACC0.86
Cap/Depr(3y)17.06%
Cap/Depr(5y)17.08%
Cap/Sales(3y)0.63%
Cap/Sales(5y)0.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)322.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.23%
EPS Next Y974%
EPS Next 2Y268.62%
EPS Next 3Y148.43%
EPS Next 5YN/A
Revenue 1Y (TTM)2.88%
Revenue growth 3Y-1.23%
Revenue growth 5Y-3.86%
Sales Q2Q%-1.73%
Revenue Next Year0.24%
Revenue Next 2Y0.91%
Revenue Next 3Y1.22%
Revenue Next 5YN/A
EBIT growth 1Y168.6%
EBIT growth 3Y6.66%
EBIT growth 5YN/A
EBIT Next Year37.4%
EBIT Next 3Y16.45%
EBIT Next 5YN/A
FCF growth 1Y206.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.25%
OCF growth 3YN/A
OCF growth 5YN/A